Simulations Plus Releases ADMET Predictor™ Version 8.5
November 30 2017 - 8:30AM
Business Wire
New HTPK Simulation Module allows chemists
to screen compound libraries using novel approach
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of
modeling and simulation solutions for the pharmaceutical,
chemicals, and consumer goods industries, today announced that it
has released version 8.5 of its best-in-class molecular
property prediction program, ADMET Predictor™.
Dr. David Miller, director of ADMET Cheminformatics, said:
“Working with our colleagues in the Simulation Sciences department,
we have merged the mechanistic oral absorption (ACAT™) and minimal
PBPK models from GastroPlus™ into this new version of ADMET
Predictor to create the High Throughput Pharmacokinetics (HTPK)
Simulation Module. This capability now allows chemists to
seamlessly combine our top-rated QSAR models with virtual rat and
human physiology models to drive lead selection and optimization
activities. This novel approach, which we are terming ‘discovery
PBPK,’ should lead to more efficient screening of candidate
molecules in early discovery and improve communication between
chemists and DMPK scientists as compounds progress into early
development. Other key improvements in this version of ADMET
Predictor include:
- New synthetic difficulty scores to
guide strategic resource allocation during drug design
- Improved Ames mutagenicity models – a
key toxicity endpoint required for all drug applications
- Optimization of spreadsheet and
model-building functions to improve speed and efficiency
- Enhanced command-line capabilities to
streamline all major program operations.”
John DiBella, president of the Lancaster division for
Simulations Plus, added: “We collaborated with a large
pharmaceutical company over several years to implement this new
‘discovery PBPK’ approach using the standalone GastroPlus and ADMET
Predictor programs, submitting several manuscripts for publication
in the process. We always had a goal in mind to integrate this
capability into an easy-to-use application, and we have now
successfully done so. The initial reception has been extremely
positive, and we have received many requests for evaluation. We
expect the new HTPK Simulation Module, as an optional add-on
license, and the other exciting new features in version 8.5 to
further the solid sales gains ADMET Predictor has realized over the
past five years as more chemistry and DMPK departments adopt our
unique solutions.”
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical and biotechnology agents.
Our software is licensed to and used in the conduct of drug
research by major pharmaceutical and biotechnology companies and
regulatory agencies worldwide. Our innovations in integrating new
and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For
more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
as filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171130005304/en/
Simulations Plus Investor
RelationsMs. Renee
Bouche661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron
Donahue651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024